MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'cox 2'. Sat, 03 Sep 2011 02:21:48 +0100 http://www.medworm.com/index.php?rid=5118991&cid=t_145618_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FwaOpAxF9HgM%2F For three decades, John LaMattina worked at Pfizer, where he rose through the ranks before heading global R&D and retiring in 2007. This meant that he was on hand as Pfizer mushroomed in size after buying Warner-Lambert and Pharmacia. And it was during this stretch that boardroom politics - notably, growing tension between Pfizer chair Bill Steere and ceo Hank McKinnell - blossomed, leading to the ascent of Jeff Kindler, who last winter suddenly resigned as ceo. These tumultuous changes (read here and here), shaped strategic decisions that led Pfizer to close facilities, eliminate research areas and fire gobs of scientists (see this). Recently, LaMattina, who is now a senior partner at Puretech Ventures, lamented the aftermath in a piece in Nature Reviews (see this). We chatted with h... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5118991 Thu, 11 Aug 2011 15:32:30 +0100 5118991 http://www.medworm.com/index.php?rid=4968823&cid=t_145618_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F23%2Fcan-a-diet-low-in-carbs-high-on-protein-help-in-the-fight-against-cancer%2F Eating a low-carbohydrate, high-protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published in Cancer Research, a journal of the American Association for Cancer Research. Eating a low-carbohydrate, high-protein diet may reduce the risk of cancer and slow the growth of tumors already present, [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4968823 Fri, 24 Jun 2011 05:21:02 +0100 4968823 http://www.medworm.com/index.php?rid=3052410&cid=t_145618_155_f&fid=38406&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FThe1xObjective%2F%7E3%2F3yzNwClgfBs%2F COX-2 is an inducible enzyme involved in prostaglandins metabolism that has been associated with cellular resistance to apoptosis both in normal and malignant epithelial cells. Over-expression of... Catch the rest of the story after the break... (Source: The 1x Objective) The 1x Objective blogs http://www.medworm.com/rss/comments.php?id=3052410 Wed, 02 Dec 2009 17:46:25 +0100 3052410 http://www.medworm.com/index.php?rid=2765979&cid=t_145618_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2009%2F09%2Flatest-version-of-argument-that-we-are.html Discussion) portion of the article was it mentioned that the authors had served as paid expert witnesses for plaintiffs’ attorneys in rofecoxib litigation. The terse disclosure statement seems at odds with JAMA’s stated policy in its Instructions for Authors that financial COI disclosure must be complete. Regardless, the information provided hardly conveyed that, as of January 2007, Krumholz had received more than $300,000 for his consulting from plaintiffs’ attorney Mark Lanier (no relationship to Mayo Clinic Proceedings Editor-in-Chief William L. Lanier, MD), which only became public in a letter to the editor of BMJ that responded to a previous article critical of Merck by Krumholz et al.Krumholz’ remuneration seems substantial until it is compared to that of another coauthor of ... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=2765979 Thu, 03 Sep 2009 21:30:00 +0100 2765979 http://www.medworm.com/index.php?rid=2761824&cid=t_145618_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2009%2F09%2Fpfizers-2300000000-settlement-no-longer.html Re the $2.3 billion dollar Pfizer settlement, in the headlines today...Health Care Renewal readers learned about it in February, here.At the time, we mentioned how little coverage the news had received, a manifestation of the anechoic effect.We said this about it then:We have posted about numerous settlements of charges of misbehavior by drug, device, insurance and other health care organizations. Stacking them all up suggests the magnitude of bad behavior by the leaders of health care organizations. Yet it's not clear that all these monetary penalties are discouraging bad behavior.In almost all cases, the monetary penalties accrue to the organization as a whole, not to the individuals whose behavior incited the settlement. And I have not so far ever heard of a case in which the organizati... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=2761824 Thu, 03 Sep 2009 15:40:00 +0100 2761824 http://www.medworm.com/index.php?rid=2349513&cid=t_145618_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F19%2Ftumor-promoting-protein-cox-2-is-the-target-of-first-joint-symposium-between-aacr-asco%2F “An inflammatory protein implicated in a variety of cancers is the target of the first joint symposium between the nation’s two premier cancer research organizations.  The presidents of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) organized the session focused on the COX-2 enzyme and cancer treatment Monday [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2349513 Mon, 20 Apr 2009 05:03:52 +0100 2349513 http://www.medworm.com/index.php?rid=2152891&cid=t_145618_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2009%2F02%2Fpfizer-settles-for-mere-2300000000.html Last week, in thee Wall Street Journal, Ron Winslow reported on this little item that slipped out at the time the giant Pfizer/ Wyeth merger was announced (see our previous post here):In a disclosure nearly drowned out by news of its $68 billion acquisition of Wyeth, Pfizer Inc. said it agreed to pay $2.3 billion to settle a federal investigation into its alleged off-label marketing of the now-withdrawn painkiller Bextra.The settlement, which requires the approval of a federal judge, would be the largest ever paid by a drug company to resolve alleged marketing missteps. It easily eclipses the $1.4 billion Eli Lilly & Co. agreed to pay earlier this month to settle similar charges related to its antipsychotic medicine Zyprexa.Pfizer mentioned the settlement in two sentences in a news rel... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=2152891 Mon, 02 Feb 2009 20:20:00 +0100 2152891 http://www.medworm.com/index.php?rid=1876476&cid=t_145618_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F419968738%2F An analysis of an infamous Vioxx study found the notorious painkiller does, indeed, double the risk of heart attacks and strokes, although the likelihood of a serious cardiovascular event lessened one year after people no longer took the pill. What’s more, other drugs in the same class, known as Cox-2 inhibitors, may pose the same risk, according to the analysis published in The Lancet. “The good news is the data suggests that the risk doesn’t persist forever. The risk goes back toward normal after a year of follow up,” Robert Bresalier of the MD Anderson Cancer Center at the University of Texas, one of the study authors, tells Reuters. The original study, known as Approve, was funded by Merck and designed to determine whether Vioxx could prevent polyps that increas... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1876476 Tue, 14 Oct 2008 02:59:26 +0100 1876476 http://www.medworm.com/index.php?rid=1720551&cid=t_145618_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F370269113%2F Despite Pfizer’s best efforts, the lawyers for the family of a woman who died four years ago after taking the Celebrex painkiller have succeeded in convincing a New Jersey state court judge that Fred should be deposed and his videotaped testimony shown in court this fall. Why does this matter? Well, Fred was ceo at Pharmacia, which Pfizer scooped up in order to gain the profits from the Celebrex painkiller. And Celebrex was a key pill for Pharmacia which, you may recall, furiously battled Merck for dominance of the nascent Cox-2 inhibitor market when both drugmakers nearly simultaneously launched their meds nearly a decade ago. Back in the day, Fred (who’s now the Schering-Plough ceo) was out there stumping for Celebrex, so his testimony can shed light on steps taken to ensure... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1720551 Wed, 20 Aug 2008 20:14:03 +0100 1720551 http://www.medworm.com/index.php?rid=1683440&cid=t_145618_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F356571056%2F Seems simple, yes? And so a group of Duke University researchers developed a hypothetical model to estimate the expected incremental number of adverse drug events that could be avoided once a drug is widely available. The upshot: “Requiring larger preapproval databases could be a cost-effective means of reducing adverse events in post-approval populations,” they write in Health Affairs. As you may recall, most industry-sponsored clinical trials of new drugs are designed to determine efficacy in order to gain regulatory approval. But the researchers note that detecting adverse drug events is “rarely considered when sample-size calculations are undertaken for clinical trials.” Thus, the statistical power to find side effects is “inherently a by-product” of... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1683440 Tue, 05 Aug 2008 17:39:31 +0100 1683440 http://www.medworm.com/index.php?rid=1258589&cid=t_145618_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F241617423%2F That’s the conclusion in a piece in the latest issue of the Journal of Cardiovascular Pharmacology and Therapeutics. The only exception is naproxen, according to the authors, who reviewed a meta-analysis published two years ago in the British Medical Journal, 138 clinical trials and observational studies involving Merck’s Vioxx, Pfizer’s Celebrex and Bextra, and such widely used painkillers as ibuprofen and diclofenac. The upshot is that the Cox-2 inhibitors - the Merck and Pfizer drugs - didn’t post a statistically significant greater risk of cardiovascular disease than the other non-steroidal anti-inflammatories. However, the Merck and Pfizer drugs did pose a greater risk than taking nothing, notes Charles Hennekens, a professor at Florida Atlantic University who ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1258589 Tue, 26 Feb 2008 17:56:21 +0100 1258589 http://www.medworm.com/index.php?rid=907145&cid=t_145618_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F161925147%2F This is hardly surprising. Dan Vasella, the drugmaker’s ceo, earlier this month himself told analysts he didn’t expect the FDA to approve Prexige, not after the Cox-2 painkiller last month was blamed for deaths and liver transplants in Australia. The drug was subsequently withdrawn there. Novartis, however, is undaunted. “Many patients cannot tolerate the gastrointestinal side effects associated with NSAID pain treatments, such as those suffering from ulcers or who are being treated with anti-coagulants like warfarin,” Jim Shannon, the drugmaker’s global head of development, says in a statement. “We believe Prexige remains an important therapy for appropriate patients with osteoarthritic pain, and we will continue discussions with the FDA.” Last m... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=907145 Thu, 27 Sep 2007 10:29:02 +0100 907145 http://www.medworm.com/index.php?rid=880358&cid=t_145618_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F158054945%2F Australian families whose relatives died or became seriously ill with liver damage after taking the Novartis Cox-2 painkiller have launched a class action lawsuit against the country’s drug regulator and the drugmaker, claiming they were “treated like guinea pigs.” Peter Archer, whose wife Elaine died in late February, tells The Sydney Morning Herald he wanted to know why the Therapeutic Goods Administration approved the drug at double the dose of what was allowed in countries such as Canada and the UK for the treatment of osteoarthritis. And he accuses Novartis of holding “some sort of secret trial”. His wife died from inoperable liver failure after taking 200 milligrams of Prexige a day for four months while she waited to see a rheumatologist. The TGA recall... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=880358 Tue, 18 Sep 2007 12:30:08 +0100 880358 http://www.medworm.com/index.php?rid=2510404&cid=t_145618_87_f&fid=34866&url=http%3A%2F%2Fwww.thecardioblog.com%2F2007%2F09%2F07%2Fwhy-vioxx-is-so-dangerous%2F This study was not considered conclusive, but if you have questions or concerns about medications you're currently taking speak with your doctor.Read | Permalink | Email this | Linking Blogs | Comments (Source: The Cardio Blog) The Cardio Blog blogs http://www.medworm.com/rss/comments.php?id=2510404 Thu, 06 Sep 2007 23:00:00 +0100 2510404 http://www.medworm.com/index.php?rid=786721&cid=t_145618_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F08%2F08%2Fa-cox-2-inhibitor-delays-the-progression-of-precancerous-pancrea%2F Filed under: Pancreatic CancerA cyclooxygenase-2 (COX-2) inhibitor, nimesulide, delays the progression of precancerous pancreatic lesions in mice, according to researchers at the David Geffen School of Medicine at UCLA. Inflammation has been shown to be a factor in many forms of cancer. According to the team, this is the first study to demonstrate the effect of an anti-inflammatory COX-2 inhibitor on the development of pancreatic cancer. This is not the first time that COX-2, an enzyme that causes inflammation, has been studied by cancer researchers. COX-2 has been studied in terms of the development and growth of breast and colon cancer also.According to the lead author Dr. Eibl, these results do not mean that everyone should take a COX-2 inhibitor to protect against cancer, but they may ... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=786721 Wed, 08 Aug 2007 04:00:00 +0100 786721